ÑÇÐÇÓÎÏ·¹ÙÍø-www.yaxin868.com

ɽ¶«ÑÇÐÇÓÎÏ·¹ÙÍø»ú´²ÓÐÏÞ¹«Ë¾Ï³´²¹Ù·½ÍøÕ¾½ñÌìÊÇ£º2025-07-04Çл»³ÇÊÐ[È«¹ú]-ÍøÕ¾µØÍ¼
ÍÆ¼ö²úÆ· :
ÍÆ¼öÐÂÎÅ
¼¼ÊõÎÄÕµ±Ç°Î»ÖÃ:¼¼ÊõÎÄÕÂ>

Ò»ÖÖ¼ì²â2ÐÍÌÇÄò²¡Ò׸лùÒò18¸öλµãÍ»±äµÄ»ùÒòоƬµÄÖÆ×÷·½·¨

ʱ¼ä:2025-07-04    ×÷Õß: ¹ÜÀíÔ±

רÀûÃû³Æ£ºÒ»ÖÖ¼ì²â2ÐÍÌÇÄò²¡Ò׸лùÒò18¸öλµãÍ»±äµÄ»ùÒòоƬµÄÖÆ×÷·½·¨
¼¼ÊõÁìÓò£º
±¾·¢Ã÷Éæ¼°»ùÒòоƬ¼ì²âÁìÓò£¬¾ßÌåÉæ¼°Ò»ÖÖ¿ìËÙ¼ì²â2ÐÍÌÇÄò²¡Ò׸лùÒò¶à¸öλµãÍ»±äµÄ»ùÒòоƬ£¬Î»µãº­¸ÇĿǰÃ÷È·Óë2ÐÍÌÇÄò²¡Ïà¹ØÒ׸лùÒò¡£
±³¾°¼¼Êõ£º
ÌÇÄò²¡ÊÇÒ»ÖÖÓÉÒȵºËØ·ÖÃÚȱÏݺÍ/»òÒȵºËØ×÷ÓÃÕϰ­ËùÖµĸ´ÔÓ´úлÐÔ¼²²¡£¬ ·¢²¡ÂÊÖðÄêÉÏÉý£¬ÎÒ¹úµÄÌÇÄò²¡·¢²¡ÈËÊýλ¾ÓÊÀ½çµÚ¶þ£¬ÆäÖÐ90%Ϊ2ÐÍÌÇÄò²¡£¬ÇÒ·¢²¡Äê ÁäÇ÷ÏòÄêÇữ¡£³ÖÐø¸ßѪÌÇËùÒý·¢µÄÂýÐÔ²¢·¢Ö¢ÒѳÉΪÉö¹¦ÄÜË¥½ß¡¢Ê§Ã÷ºÍÐÄÄÔѪ¹Ü¼²²¡ µÄÖ÷ÒªÔ­Òò£¬¸ø¸öÈË¡¢Éç»áºÍ¹ú¼ÒÒ½ÁƱ£½¡´øÀ´Á˳ÁÖØµÄ¸ºµ££¬³ÉΪȫÇòÐÔµÄÉç»áÎÀÉúºÍ¾­ ¼ÃÎÊÌâ¡£ÓÉÓÚT2DM¾ßÓмÒ×åÐÔÌØÕ÷£¬ÇÒ²»Í¬ÖÖ×å¼ä·¢²¡ÂÊ´æÔÚÃ÷ÏÔ²îÒ죬ÁíÍâͬÂÑË«ÉúºÍ ÒìÂÑË«Éú¸öÌå·¢²¡ÂʺͲ¡ÇéÒ²²»Í¬£¬Òò´ËÒÅ´«³É·ÖÔڸò¡µÄ·¢²¡ÖÐÆðÖØÒª×÷Óá£Òò´Ë£¬Í¨¹ý Á¬Ëø»ò¹ØÁª·ÖÎöÈ·¶¨ÌÇÄò²¡µÄÒ׸лòÖ²¡»ùÒò£¬¶ÔÓÚ´Ó»ùÒò½Ç¶È²ûÊÍÌÇÄò²¡·¢²¡»úÖÆÓÐÖØ ÒªÒâÒå¡£»ùÒòоƬÊǽüÄêÀ´ÐËÆðµÄÒ»ÏîÖØÒªÉúÎï¼¼Êõ£¬Ô½À´Ô½¶àµØÓ¦ÓÃÓÚ»ùÒò¶à̬ÐÔ·Ö ÎöºÍÕï¶Ï[1][2]¡£Ëæ×Å»ùÒòоƬ¼¼ÊõµÄ·¢Õ¹£¬µ½2007Äê[3]ÓÃÈ«»ùÒò×éSNP»ùÒòоƬ½øÐÐ ÌÇÄò²¡Ò׸лùÒòɸ²éµÄÑо¿Ñ¸ËÙÔö¶à£¬Diabetes Gene DiscoveryGroup[4]£¬Finland-US Investigation of NIDDM Genetics (FUSION)[5]£¬deC0DEGenetics[6]£¬DiaGenm µÈÑо¿Ê¹ Óà Illumina 100K »ò Illumina 300KSNP »ùÒòоƬ£¬Diabetes Genetics Initiative , Wellcome Trust Case Control Consortium ,Pima[10], Starr County, Texas[11], Old Order Amish[12],Framingham Health Study[13]µÈÑо¿Ê¹Óà Affymetrix 100K »ò Affymetrix 500K оƬ£¬Japanese multi-disease collaborativegenome scan[14]ʹÓà JSNP Genome Scan IOOK SNP оƬ£¬BioBank Japan[15]ʹÓö¨ÖÆµÄ 268K SNP оƬ¡£ÕâЩÑо¿Öз¢ÏÖÁËÐí¶àеÄÒ׸лùÒòλµãÓë2ÐÍÌÇÄò²¡Óйأ¬×ܽáĿǰÒÑ·¢ÏÖµÄ Óë2ÐÍÌÇÄò²¡ÓйصÄÒ׸лùÒòλµã(risk variants)Ö÷ÒªÓÐÒÔϼ¸Àà(1)ͨ¹ýºòÑ¡»ùÒò¹ØÁª·ÖÎö(candidate-gene associations)È·¶¨µÄÒ׸лù ÒòλµãProl2AlaλÓÚ¹ýÑõ»¯ÎïøÌåÔöÖ³»î»¯ÊÜÌågamma»ùÒò(PPARG£¬peroxisome proliferator-activated receptor gamma)£¬¸ÃʯÂí thiazolidinedione @ÔÂÒĵºËØii1 Ãô¼ÁµÄ°Ðµã¡£Glu23LysλÓÚÄÚÏòÕûÁ÷ÐͼØÀë×ÓͨµÀÑǼÒ×åJ»ùÒò(KCNJll£¬the potassium inwardly rectifying channel, subfamily J, member 11)¸Ã»ùÒò±àÂë»ÇëåÀཱུÌÇÒ©µÄ¸ï°Í µã¦Ï(2)ͨ¹ý»ùÓÚ΢ÎÀÐǶà̬ÐÔ¹ØÁª·ÖÎöÈ·¶¨µÄÒ׸лùÒòλµãrs7903146λÓÚ TCF7L2»ùÒòÄÚº¬×ÓÇø£¬¸Ã»ùÒò±àÂëWntÐźÅͨ·ÖÐÒ»ÖÖÖØÒªµÄת¼Òò×Ó¡£¸ÃλµãÔÚĿǰËù ÓÐÒÑÖª2ÐÍÌÇÄò²¡Ïà¹ØµÄÒ׸лùÒòÖÐЧӦ×îÇ¿¡£(3)ͨ¹ý´ó¹æÄ£ºòѡͨ·Ñо¿È·Á¢µÄÒ׸лùÒòλµãrsl0010131λÓÚ WFSl (Wolfram syndrome 1)»ùÒòÄÚº¬×ÓÍâÏÔ×Ó½»½ç£¬¸Ã»ùÒò¿ÉÄܲÎÓëµ÷½âbetaϸ°û¹¦ÄÜ¡£ rs757210λÓÚHNFlB (¸Îϸ°ûºËÒò×Ó1B)»ùÒòÄÚº¬×ÓÇø£¬¸Ã»ùÒòÓëÒȵº·¢ÓýºÍ¹¦ÄÜÓйØ¡£
(4)ͨ¹ýÈ«»ùÒò¹ØÁª·ÖÎöÈ·¶¨µÄÒ׸лùÒòλµãrs8050136λÓÚFTO»ùÒòÄÚº¬×Ó Çø£»rslll875 λÓÚ HHEX/IDE(hematopoietically expressed homeobox[HHEX]/insulin degrading enzyme) SESTffif 7. 7kb^h £»rs7754840^TCDKALl (CDK5 regulatory subunit associated protein 1-like 1)»ùÒòÄÚº¬×ÓÇø£»rs4402960 λÓÚ IGF2BP2 (insulin-like growth factor 2 mRNA binding protein 2)»ùÒòÄÚº¬×ÓÇø£»rsl0811661 λÓÚ CDKN2A/ B (cyclin-dependent kinase inhibitors 2a and 2b)»ùÒòÉÏÔL,125kb ´¦£»rsl3266634 ±à Âë SLC30A8 (solute carrier family 30, member 8)»ùÒò R325W Í»±ä¡£(5)ͨ¹ý¶ÔÈ«»ù Òò×鹨Áª·ÖÎö½øÐÐmeta·ÖÎöÈ·¶¨µÄÒ׸лùÒòλµãrsl0923931 λÓÚN0TCH2 (Notch homologue 2£¬Drosophila)»ùÒòÄÚº¬×ÓÇø£¬¸Ã»ùÒò²ÎÓëÒÈÏÙ·¢Óý£» rs4607103 ^ T ADAMTS9(ADAM metallopeptidase withthrombospondin type 1 motif 9)»ùÒòÉÏÓÎ 38kb ´¦£»rsl2779790 ÁÙ½ü CAMKlD(calcium/calmodulin¡ªdÓ¡endent protein kinase ID)»ùÒò£»rs864745 λÓÚ JAZFl (juxtaposed with another zinc finger gene 1)»ùÒòÄÚº¬×ÓÇø£»rs7961581 λÓÚ TSPAN8/LGR5 (tetraspanin 8 (TSPAN8)/leucine-rich repeat-containing G-proteincoupled(LGR5)) ¡ö @ ÄÚ ^¡¤¨“ IK £»rs7578597 IS Âë THADA (thyroid adenomaassociated) ¡¤@¦³1187¦¡£¬$¡£ÈçºÎ¸ßͨÁ¿¼ò±ã¿ìËٵĶÔÕâЩÒÑÖªÒ׸лùÒòλµã½øÐзÖÐÍ£¬¶ÔÓÚÑéÖ¤²»Í¬ÈËȺÕâ ЩλµãÏà¹ØÐÔ²îÒ죬»òÖØ¸´¹ØÁª·ÖÎö½á¹û£¬¼´(implication studies)ÓÐÖØÒªÒâÒå¡£²¢ÇÒ ¶Ô´óÑù±¾ÈËȺ½øÐÐÕâЩλµã·ÖÐÍ£¬¿ÉÅжÏͨ¹ýÕâЩλµã´Ó»ùÒò½Ç¶ÈÔ¤²â2ÐÍÌÇÄò²¡µÄЧÄÜ (Meigs, J. B. , Prediction of type 2 diabetes :the dawn ofpolygenetic testing for complex disease. Diabetologia, 2009. 52 (42) :p. 568-570.)¡£ÀýÈç Valeriya Lyssenko µÈ(Narayan, K. ¦¬. V. and ¦¬. B. Weber, Clinical Risk Factors, DNA Variants, and the Development of Type 2 Diabetes. New England Journal ofMedicine,2009. 360(13) p. 1360-1360.)¶Ô 16£¬061 ÃûÈðµäÈËºÍ 2770 ·ÒÀ¼ÈË·ÖÎö 16 ÖÖ SNP(TCF7L2 (rs7903146)£¬ KCNJll (rs5219)£¬PPARG (rsl801282)£¬CDKALl (rs7754840)£¬IGF2BP2 (rs4402960)£¬CDKN2A/ CDKN2B(rsl0811661)£¬FTO (rs9939609)£¬HHEX (rs1111875)£¬SLC30A8 (rsl3266634)£¬ WFSl (rsl0010131) , JAZFl (rs864745)£¬CDC123/CAMK1D(rsl2779790)£¬TSPAN8/ LGR5(rs7961581), THADA(rs7578597), ADAMTS9(rs4607103), and N0TCH2(rsl0923931).) »ùÒòÐÍ£¬ÒÔ¼ì²âÕâЩÒ׸лùÒòλµãÔ¤²â2ÐÍÌÇÄò²¡µÄЧÄÜ£¬·¢ÏÖÔÚ³£¹æÒ׸ÐÒòËØÉÏ£¬¼ÓÈë Ò׸лùÒòÐÅÏ¢£¬¿ÉÌá¸ßÔ¤²âЧÄÜ(¼ÓÈëÒ׸лùÒòÐÅÏ¢ºó£¬ROCÇúÏßÏÂÃæ»ýAUCÓÉ0. 74ÉýΪ 0. 75£¬P= 1. OXliT4)¡£Lango µÈ(Lango£¬H. ,et al. ,Assessing thecombined impact of 18 common genetic variants of modest effect sizes on type 2diabetes risk. Diabetes, 2008. 57 (11) :p. 3129-35.)¶Ô2£¬598Ãû¶ÔÕÕºÍ2£¬309Ãû2ÐÍÌÇÄò²¡»¼Õß·ÖÎö18ÖÖSNP·ÖÐÍ ·¢ÏÖ£¬ÒÔЯ´ø10-12¸öÒ׸еÈλ»ùÒò×éΪ»ù×¼£¬Ð¯´øáê25¸öµÈλ»ùÒò×éORΪ4. 2 (95% CI 2. 11-8. 56)¡£ÌáʾЯ´ø´óÁ¿Ò׸еÈλ»ùÒò¸öÌ廼²¡¿ÉÄÜÐÔ¸ü´ó¡£¶Ô´«Í³µÄÌÇÄò²¡Ò׸лùÒò¼ì²â·½·¨Ö÷Òª°üÀ¨PCR-RFLP¡¢AS-PCRºÍDNA²âÐò·½·¨ µÈ£¬ÕâЩ·½·¨ÔÚ»ùÒòÍ»±ä¼ì²âÖÐÆðÁËÖØÒª×÷Ó㬵«ÆÕ±é´æÔÚ×ÅÃ÷ÏԵIJ»×㣬´«Í³µÄÌÇÄò²¡Ò× ¸Ð»ùÒò¼ì²â·½·¨Ö÷Òª°üÀ¨PCR-RFLP¡¢AS-PCRºÍDNA²âÐò·½·¨µÈ£¬ÕâЩ·½·¨ÔÚ»ùÒòÍ»±ä¼ì²â ÖÐÆðÁËÖØÒª×÷Ó㬵«ÆÕ±é´æÔÚ×ÅÃ÷ÏԵIJ»×㣬ÖîÈç¼ì²â»ùÒòλµãÓÐÏÞ¡¢ºÄʱ³¤¡¢²Ù×÷·±ËöµÈ£¬ ²»ÊÊÓÃÓÚ´óÅúÁ¿¡¢ÏµÍ³¼ì²â£¬¸øÌÇÄò²¡µÄÁÙ´²Õï¶Ï´øÀ´À§ÄÑ¡£
PCR-RFLP·½·¨ÊǾ­µäµÄÉúÎïѧ·½·¨£¬µ«ÓÉÓÚÏÞÖÆÐÔÄÚÇÐøʶ±ðλµãÓÐÏÞ£¬ÄÑÒÔʵ ÏÖͬʱ¼ì²â¶à¸öλµã£¬ÇÒºÄʱ½Ï³¤£»AS-PCR·½·¨ËäÄÜ׼ȷ¼ì²âÍ»±ä£¬µ«ÒªÇóÀ©ÔöÌõ¼þ·Ç³£ ÓÅ»¯£¬ÇÒÒýÎïÒªÓи߶ȵÄÌØÒìÐÔ£¬·ñÔòÒ׳öÏÖ¼ÙÏÞÐÔ»ò¼ÙÑôÐÔ½á¹û£»DNA²âÐòËäÊÇĿǰ¹«ÈÏ µÄ¼ì²âÐÂÍ»±äµÄ½ð±ê×¼£¬µ«ÓÉÓÚÆä¶ÔÌØÊâ½á¹¹DNAÐòÁÐÎÞ·¨²âÐò£¬¶øÇÒÖ»ÓÐÒìÖÊÐÔˮƽ> 25%ʱ²ÅÄܼì³ö£¬¶øÁÙ´²³£Óñ걾ÍâÖÜѪ°×ϸ°ûÖÐÒìÖÊÐÔˮƽͨ³£¶¼´ï²»µ½Õâ¸ö±ê×¼£¬Òò ´ËºÜÒש¼ì¡£Ä¿Ç°³£ÓõÄSNaPshotºÍSequenom¼¼Êõ£¬Ó¦Óóɱ¾¸ß£¬ÔòÐèÒª¹ºÂò°º¹óµÄרÃÅÉè ±¸¡£±¾¿ÎÌâ×é²ÉÓö¨ÖÆ»ùÒòоƬ¼¼Êõ£¬Í¨¹ý×Ô¶¯»¯»ùÒòоƬµãÑùÒǽ«Ô¤ÏȺϳɵÄ̽ÕëµãÑù ÓÚÈ© »ùÐÞÊεIJ£Á§ÔØÆ¬ÉÏ£¬¹¹³ÉרÃÅÕë¶Ô2ÐÍÌÇÄò²¡´óÑù±¾¹ØÁª·ÖÎöÓõĻùÒòоƬ£¬Îª¼ì ²â¸ÃоƬ¼ì²âµÄ׼ȷÐÔºÍÖØ¸´ÐÔ£¬±¾·¢Ã÷¶ÔÍâÖÜѪÑù±¾Ó¦ÓøÃоƬ½øÐмì²â£¬²¢²âÐòÑéÖ¤ оƬ¼ì²â½á¹û£¬Ð¾Æ¬¼ì²â½á¹ûÓë²âÐò½á¹ûÏà·û¡£

·¢Ã÷ÄÚÈÝ
±¾·¢Ã÷µÄÄ¿µÄÔÚÓÚÌṩһÖÖ¼ì²â2ÐÍÌÇÄò²¡Ò׸лùÒò18¸öλµãÍ»±äµÄ»ùÒòоƬ¡£±¾·¢Ã÷µÄÁíÒ»¸öÄ¿µÄÔÚÓÚÌṩһÖÖ°üÀ¨ÉÏÊö»ùÒòоƬµÄÊÔ¼ÁºÐ¡£ÎªÊµÏÖÉÏÊöÄ¿µÄ£¬±¾·¢Ã÷Ê×ÏÈÌṩһÖÖ¼ì²â2ÐÍÌÇÄò²¡18»ùÒòλµãÍ»±äµÄ»ùÒòо Ƭ£¬Æä°üÀ¨¹Ì¶¨ÔÚ¹ÌÏàÔØÌåÉϵÄÓÃÓÚ¼ì²â2ÐÍÌÇÄò²¡Ò׸лùÒòµÄÌØÒìÐԹѺËÜÕËá̽Õ룬Æä ºËÜÕËáÐòÁÐÈçSEQ ID No. 1 36Ëùʾ¡£ËùÊö¹ÌÏàÔØÌåÓÅѡΪȩ»ù²£Æ¬¡£ËùÊö̽Õë5¡¯¶ËÓÐ 15¸ö¶à¾ÛT£¬5¡¯¶Ë¾­ÐÞÊΰ±»ù»ùÍźó¹Ì¶¨ÔÚÈ©»ù²£Æ¬ÉÏ¡£ÉÏÊö»ùÒòоƬµãÕ󲼿ØÎª²£Á§Ð¾Æ¬Îª117¸öÑùµã×é³ÉµÄ10ÐÐX 12ÁеľØÕó¼û ¸½Í¼1£¬°üÀ¨ÖÊ¿ØÏµÍ³ºÍ¼ì²âϵͳ£¬ÖÊ¿ØÏµÍ³Îª(1)оƬÑôÐÔ¶ÔÕÕ£¬ÎªSEQID No. 1 14̽ ÕëµÄµÈÁ¿»ìºÏµÄÈÜÒº£¬Éè¼Æ²¼¿ØÓÚ×óϽǣ¬×÷ΪÑôÐÔ¶ÔÕյ㣬¹²3¸öÑôÐÔ¶ÔÕÕÑùµã£»(2)оƬ ƽÐжÔÕÕ£¬²ÉÓÃ25uMµÄ̽ÕëÈÜÒºµãÑù£¬Ã¿ÖÖ̽ÕëÆ½Ðеã3¸öµã(3¸öÖØ¸´)£¬¼´Ã¿3¸öµã¼ì²â Ò»¸öµÈλ»ùÒòÐÍ£»×óÓÒ¹²6¸öµã£¬¹²Í¬¹¹³ÉÒ»¸ö»ùÒòλµã¼ì²âÇø£»(3)оƬÒõÐÔ¶ÔÕÕ£¬ÎªµãÑù ÈÜÒºÒÔ¼°Ë«ÕôË®£¬¸÷Èý¸öµã£¬¹²6¸öÒõÐÔ¶ÔÕÕÑùµã£¬Î»ÓÚÓÒϽǡ£±¾·¢Ã÷»¹½øÒ»²½ÌṩËùÊö»ùÒòоƬµÄÖÆ±¸·½·¨£¬Æä°üÀ¨Èçϲ½ÖèºÏ³ÉSEQID No. 1 36ËùʾµÄ̽Õ룬̽ÕëÔںϳÉʱ5¡¯¶Ë¶àºÏ³É15¸ö¶à¾ÛT£¬²¢¾­°±»ù»ùÍÅÐÞÊΣ¬½«ÐÞÊÎ ºóµÄ̽ÕëÓÃTE BufferÖÆ³É50uMµÄÈÜÒº£¬µãÑùǰ°´1 1±ÈÀýÓëµãÑùÈÜÒº»ìºÏ£¬ÖÕŨ¶ÈΪ 25 ¦Ì M £»½«²£Æ¬È©»ù»¯ÐÞÊΣ»½«ÖÕŨ¶ÈΪ25 ¦Ì MµÄ̽ÕëÈÜÒº°´µãÑù¾ØÕóÅÅÁÐÔÚ96¿×°å£»PBS ÈÜÒºÇåÏ´µãÑùÒǵãÑùÕ룬УÕý£¬°´Í¼1¾ØÕóµãÑù£»Ô¤µã20´Î£¬µã¼ä¼ä¾à200um£¬ÊÒÎÂË®ºÏ¹Ì¶¨ 24h¡£Ôڹ̶¨ºó°´ÏÂÊö²½Öè½øÐÐÏ´µÓÊÒÎÂÏÂ2XSSC-0. 1% SDSÏ´µÓÒºÖÐÉÏÏÂÌá·Å2-3´Î£¬ 1XSSC-0. 1% SDSÏ´µÓÒºÖÐÉÏÏÂÌá·Å2min£¬0.2 X SSCÏ´µÓÒºÖÐÉÏÏÂÌá·Å2min£¬Ë«ÕôË®Öгé Ìá2-3´Î£¬ÀëÐÄ˦¸É¡£½øÒ»²½£¬±¾·¢Ã÷»¹ÌṩһÖÖº¬ÓÐÉÏÊö»ùÒòоƬµÄ¼ì²âÊÔ¼ÁºÐ£¬Æä»¹°üÀ¨ÓÃÓÚÀ©Ôö Ò׸лùÒòλµãËùÔÚÇøÓòµÄÒýÎÒýÎïÐòÁÐΪSEQ ID No. 37 72ËùʾµÄ¹ÑºËÜÕËᣬËùÀ©ÔöÇø ÓòΪSEQ ID No. 73 90Ëùʾ¡£´ËÍâÆä»¹¿ÉÒÔ°üÀ¨ÒÔÏÂÊÔ¼ÁÖеÄÒ»ÖÖ»ò¶àÖÖÔÓ½»Òº¡¢·â±ÕÒº¡¢PCR»º³åÒº¡¢ dNTPs¡¢DNA¾ÛºÏøÒÔ¼°MgC12¡£¾ßÌ嵨£¬ÎªÊµÏÖÉÏÊöÄ¿µÄ£¬±¾·¢Ã÷²ÉÓÃÒÔϼ¼Êõ²½Öè
(1)ͨ¹ý¶Ô2ÐÍÌÇÄò²¡Ò׸лùÒòλµãÍ»±ä½øÐÐɸÑ¡£¬Ó¦ÓÃPrimer3.0(http:// frodo. wi. mit. edu/primer3/)ºÌ¿Ú NCBI BLAST (http //blast, ncbi. nlm. nih. gov/Blast. Cgi)¸¨ÖúÉè¼ÆÏà¹ØÌ½ÕëºÍÒýÎʹĿµÄƬ¶ÎÀ©Ôö¡¢ÔÓ½»·´Ó¦ÄÜÔÚͬһÌõ¼þϽøÐС£ÆäºËÜÕ ËáÐòÁÐÈçSEQ ID N o. 1 72Ëùʾ¡£ÕâЩ̽Õë·ÖΪÒ׸Ðλµã¼ì²â̽ÕëºÍ·ÇÒ׸Ðλµã¼ì²â̽ Õ룬¶ÔÏÂÊö SNP λµãrsl801282¡¢rs5219¡¢rs7903146¡¢rsl0010131¡¢rs757210¡¢rs4430796¡¢ rs8050136¡¢rsllll875¡¢rs7754840¡¢rs4402960¡¢rsl0811661¡¢rsl3266634¡¢rsl0923931¡¢ rs4607103¡¢rs7578597¡¢rs864745¡¢rsl2779790¡¢rs7961581 (¾ßÌåÈç±í 1 Ëùʾ)¡£(2)оƬµãÕ󲼿ز£Á§Ð¾Æ¬Îª117¸öÑùµã×é³ÉµÄ10ÐÐX 12ÁеľØÕ󣬰üÀ¨ÖÊ¿Ø ÏµÍ³ºÍ¼ì²âϵͳ£¬ÖÊ¿ØÏµÍ³Îª(1)оƬÑôÐÔ¶ÔÕÕ£¬ÎªËùÑ¡µÄ¸÷¹ÑºËÜÕËá̽ÕëµÄµÈÁ¿»ìºÏµÄ ÈÜÒº(SEQ ID No.l 36)£¬Éè¼Æ²¼¿ØÓÚ×óϽǣ¬¹²3¸öÑôÐÔ¶ÔÕÕÑùµã£»(2)оƬƽÐжÔÕÕ£¬ ²ÉÓÃ25uMµÄ̽ÕëÈÜÒº£¬¸÷λ̽ÕëÆ½Ðеã3¸öµã£¬¼´Ã¿3¸öµã¼ì²âÒ»¸öµÈλ»ùÒòÐÍ£»×óÓÒ¹² 6¸öµã£¬¹²Í¬¹¹³ÉÒ»¸ö»ùÒòλµã¼ì²âÇø£»(3)оƬÒõÐÔ¶ÔÕÕ£¬ÎªµãÑùÈÜÒº(Micro Spotting Solution Plus 2X£¬Telechem)ÒÔ¼°Ë«ÕôË®£¬¸÷Èý¸öµã£¬¹²6¸öÒõÐÔ¶ÔÕÕÑùµã£¬Î»ÓÚÓÒϽǣ¬ ̽Õë¾ßÌåÅŲ¼¼ûͼ1¡£(3)°üÀ¨²£Æ¬È©»ùÐÞÊΣ¬µãÑù£¬¹Ì¶¨£¬DNAÄ£°åÌáÈ¡£¬PCRÀ©ÔöºÍ±ê¼Ç£¬ÔÓ½»£¬Ï´µÓ£¬Ó« ¹â¼ì²âÔÚÄڵĶàÖÖ¸´ÔÓ·´Ó¦¡£(4)Ó«¹âÐźżì²â£¬Í¨¹ýScanAlyzeÈí¼þ·ÖÎö¸÷µãÓ«¹âÇ¿¶È£¬Í¨¹ýÒ׸ÐλµãºÍ·ÇÒ× ¸ÐλµãÓ«¹âÐźÅÇ¿¶È²½Ö裬ȷ¶¨»ùÒòÐÍ¡£Ò»ÖÖ¼ì²â2ÐÍÌÇÄò²¡18¸öÒ׸лùÒòλµãµÄ΢ÕóÁÐÐ¾Æ¬ÖÆ±¸²½ÖèÊÇ(1)ÒÔÈ©»ù²£Æ¬ÎªÔØÌ岣Ƭ¾­¸õËáÏ´Òº½þÅݹýÒ¹£¬È¥³ý±íÃæÓлúÎïµÈÔÓÖÊ£¬È»ºóÕôÁóË®ÇåÏ´£¬ÔÙÓÃ25%°± Ë®½þÅݹýÒ¹£¬Ë®Ï´¡£pHΪ4. 5°±±û»ùÈý¼×Ñõ»ù¹èÍéµÄ95%ÒÒ´¼½þÅÝ20min£¬ÔÙÓÃ95%ÒÒ´¼ ³¬ÉùÇåÏ´£¬´¿Ë®³¬ÉùÇåÏ´£¬115¡ãCºæ¿¾45min£¬×îºóÔÚ5 %µÄÎì¶þÈ©ÈÜÒºÖÐ50min£¬³¬ÉùIOmin£¬ ˮϴÁ½´Î£¬ÖÃÓÚÊÒθÉÔﱸÓá£(2)̽ÕëºÍÒýÎïÉè¼Æ±¾·¢Ã÷ÑÐÖÆµÄ΢ÕóÁÐоƬ¿É¼ì²âĿǰ¹úÄÚÍⱨµÀµÄÓë2ÐÍÌÇÄò²¡Ïà¹ØµÄ18 ¸öÒ׸лùÒòλµã¡£Ó¦Óà Primer3. 0 (http//frodo. wi. mit. edu/primer3/)ºÍ NCBI BLAST (http://blast, ncbi. nlm. nih. gov/Blast. cgi)¸¨ÖúÉè¼ÆÏà¹ØÌ½ÕëºÍÒýÎÉè¼ÆÌ½Õë 36Ìõ£¬ÍË»ðζÈΪ58Ê¿2¡ãC £»ÒÔ¼°À©ÔöÏàӦƬ¶ÎµÄ18¶ÔÒýÎλµãº­¸ÇÁËĿǰÃ÷È·µÄÓë2 ÐÍÌÇÄò²¡Ïà¹ØµÄÒ׸Ðλµã¡£(3)оƬµãÕ󲼿ز£Á§Ð¾Æ¬Îª117¸öÑùµã×é³ÉµÄ10ÐÐX 12ÁеľØÕ󣬰üÀ¨ÖÊ¿ØÏµÍ³ºÍ¼ì²âϵͳ£¬ ÖÊ¿ØÏµÍ³Îª(1)оƬÑôÐÔ¶ÔÕÕ£¬ÎªËùÑ¡µÄ¸÷¹ÑºËÜÕËá̽ÕëµÄµÈÁ¿»ìºÏµÄÈÜÒº(SEQ ID No. 1 36)£¬Éè¼Æ²¼¿ØÓÚ×óϽǣ¬¹²3¸öÑôÐÔ¶ÔÕÕÑùµã£»(2)оƬƽÐжÔÕÕ£¬²ÉÓÃ25uMµÄ̽Õë ÈÜÒº£¬¸÷λ̽ÕëÆ½Ðеã3¸öµã£¬¼´Ã¿3¸öµã¼ì²âÒ»¸öµÈλ»ùÒòÐÍ£»×óÓÒ¹²6¸öµã£¬¹²Í¬¹¹³ÉÒ» ¸ö»ùÒòλµã¼ì²âÇø£»(3)оƬÒõÐÔ¶ÔÕÕ£¬ÎªµãÑùÈÜÒº(Micro Spotting Solution Plus 2X£¬ Telechem)ÒÔ¼°Ë«ÕôË®£¬¸÷Èý¸öµã£¬¹²6¸öÒõÐÔ¶ÔÕÕÑùµã£¬Î»ÓÚÓÒϽǣ¬Ì½Õë¾ßÌåÅŲ¼¼ûͼ1¡£(4)оƬµÄµãÑù£¬¹Ì¶¨ºÍÏ´µÓ½«ÖÕŨ¶ÈΪ25 ¦Ì MµÄ̽ÕëÈÜÒº°´µãÑù¾ØÕó(µãÑù¾ØÕóÅŲ¼¼ûͼ1)ÅÅÁÐÔÚ96¿×°å£»PBSÈÜÒºÇåÏ´µãÑùÒÇ(SpotBot3£¬Telechem)µãÑùÕ룬УÕý£¬°´Í¼1¾ØÕóµãÑù£»Ô¤µã20´Î£¬µã¼ä¼ä¾à200um£¬ÊÒÎÂË®ºÏ¹Ì¶¨24h¡£ËùÊöоƬϴµÓ¹ý³ÌΪÊÒÎÂÏÂ2XSSC-0. 1% SDSÏ´µÓÒº ÖÐÉÏÏÂÌá·Å2-3´Î£¬1XSSC-0. 1% SDSÏ´µÓÒºÖÐÉÏÏÂÌá·Å2min£¬0. 2X SSCÏ´µÓÒºÖÐÉÏÏÂÌá ·Å2min£¬Ë«ÕôË®ÖгéÌá2-3´Î£¬ÀëÐÄ˦һÖÖ¼ì²â2ÐÍÌÇÄò²¡18¸öÒ׸лùÒòλµãµÄ΢ÕóÁÐоƬ¼ì²â²½ÖèÊÇ(1)ÊÕÈ¡²¡È˱걾£¬ÌáÈ¡DNAÄ£°å¡£(2)²ÉÓÃSEQ ID No. 37 72ËùʾÒýÎÀ©ÔöÄ¿µÄƬ¶Î¡£PCR·´Ó¦ÒºÊÇÓÉ 10Xbuffer,10ymol/L µÄÕýÏòÒýÎlOymol/L ·´Ïò¹­Ø­Î25mmol/L MgCl2, IOmmol/ LdNTPs (º¬0. 5nM Cy3_dCTP£¬ÓÉAmersham¹«Ë¾Ìṩ)ºÍÎÞ¾úË«ÕôË®×é³É¡£À©ÔöÌõ¼þΪ95¡ãC Ô¤±äÐÔ3min, 35¸öÑ­»·(94¡ãC±äÐÔ30s, 55¡ãCÍË»ð30s, 72¡ãCÑÓÉì30s)£¬72¡ãCÑÓÉì7min¡£(3½ï0 ²úÎï1001±äÐÔ£¬ÖèÀä¡£(4) 42¡ãCÔ¤ÔÓ½»30min·â±Õ·ÇÌØÒìÐÔ½áºÏ£»Ô¤¼ÓÈȱäÐÔµÄCy3_DNAÓëÔÓ½»Òº(DIG Easy Hyb£¬R0Che)°´1 10»ì„ò£¬42¡ãCÔÓ½»4h£¬Ã¿¸öÑù±¾Í¬Ê±ÓÃÁ½¸öÏàͬ¾ØÕóÖØ¸´¼ì²â¡£(5)ÊÒÎÂÏÂ2XSSC-0. 1% SDSÏ´µÓÒºÖÐÉÏÏÂÌá·Å2-3´Î£¬1XSSC-0. 1% SDSÏ´µÓ ÒºÖÐÉÏÏÂÌá·Å2min£¬0. 2 X SSCÏ´µÓÒºÖÐÉÏÏÂÌá·Å2min£¬Ë«ÕôË®ÖгéÌá2_3´Î£¬ÀëÐÄ˦¸É¡£(6) LuxScan 10K-A (CapitalBio, Beijing)оƬɨÃèÒÇÔÚ 570nm ²¨³¤²É¼¯Ð¾Æ¬Í¼ Ïñ(·Ö±æÂÊ10um£¬¼¤¹âÆ÷¹¦ÂÊ95%£¬PMTÔöÒæ650)¡£ËùµÃ½á¹ûͨ¹ýScanAlyzeÈí¼þ·ÖÎö£¬ »ñµÃоƬ·ÖÎöÊý¾Ý¡£¸ù¾ÝÓ«¹âÐźÅÇ¿¶È±ÈÖµ(Ò׸еÈλ»ùÒò¸÷µãÓ«¹âÇ¿¶È¾ùÖµ/·ÇÒ×¸ÐµÈ Î»»ùÒò¸÷µãÓ«¹âÇ¿¶È¾ùÖµ£¬¾ßÌå·ÖÎö·½·¨Í¬ScanAlyzeÈí¼þÊÖ²á½éÉÜ)£¬Èô±ÈÖµ´óÓÚ3ÔòÅРΪÒ׸еÈλ»ùÒò´¿ºÏÐÍ£¬ÔÚ0. 3ÒÔÏ·ÇÒ׸еÈλ»ùÒò´¿ºÏÐÍ£¬½éÓÚ0. 3-3Ö®¼ä£¬ÅÐΪÔÓºÏÐÍ¡£ (±ÈÖµºâÁ¿±ê×¼²Î¿¼Du W,Marsac C,Kruschina M,Ortigao F,Florentz C. Functionalized self-assembled monolayer ongold for detection of human mitochondrial tRNA gene mutations. Anal Biochem. 2003 Nov 1£»322(1) 14-25.)(7)¸ÃоƬ¾ßÓÐÏÂÓŵã¢ÙÒ»ÕÅоƬ¿Éͬʱ¼ì²â1-5·Ý²»Í¬±ê±¾µÄ18¸öÒ׸лù Òòλµã£»¢Ú²Ù×÷¼òµ¥£¬±ê¼ÇÀ©Ôöͬ²½Íê³É£¬ÔÚ±£Ö¤Ä¿µÄƬ¶Î·á¶Èͬʱ£¬Íê³É±ê¼Ç·´Ó¦£¬ÎÞÐèÏÔ É«£»¢Û¿É¼ì²âĿǰÒÑÃ÷È·µÄ18¸öÒ׸лùÒòλµã£¬ÎÞ©¼ìºÍÎóÕï¡£¢Ü¸ù¾ÝÒ°ÉúÐͺÍÍ»±äÐÍÓ« ¹âÇ¿¶È±ÈÖµ£¬ÒÔ¼°±³¾°ÐźÅÇ¿¶È£¬Åжϱ»¼ìλµã»ùÒòÐÍ£¬½á¹û¿ÆÑ§¿Í¹Û¡£¸÷λµãƬÄÚÆ½ÐÐ¶Ô ÕÕµã¼äÓ«¹âÇ¿¶ÈÒ»ÖÂÐԺ㬱äÒìϵÊýСÓÚ6. 4%£¬Æ¬¼äͬλµã¼ä±äÒìϵÊýСÓÚ8. 63%£¬¼ì²â ½á¹û¼ÙÑôÐÔÂÊΪ2. 65%£¬¼ÙÒõÐÔÂÊΪ0. 76% £»¢Ý³É±¾µÍ£¬·´Ó¦Ìåϵ΢Á¿£¬Ò»´ÎÔÓ½»·´Ó¦Ìåϵ Ϊ100΢Éý¡£·¢Ã÷µÄÓŵãºÍЧ¹û±¾·¢Ã÷ÑÐÖÆÁËÒ»ÖÖ¿ìËÙ¼ì²â18¸ö2ÐÍÌÇÄò²¡Ïà¹ØÎ»µãµÄ΢ÕóÁÐоƬ¡£¸ÃоƬ¿É ¢Ù18¶ÔÒýÎïÀ©ÔöºÍCy3Ó«¹âȾÁϱê¼Ç¿ÉÔÚͬһÌõ¼þϽøÐУ¬ÔÚ±£Ö¤ºóÐø·´Ó¦ËùÐèDNAÁ¿µÄ ͬʱÍê³É±ê¼Ç£¬Ê¡Ê±²¢½µµÍÁËʵÑé³É±¾¡£¢ÚCy3Ó«¹âȾÁϱê¼Ç£¬Ï´Æ¬ºó¿ÉÖ±½ÓÓ«¹âɨÃèÒÇ¹Û ²ì½á¹û£¬ÎÞÐèÏÔÉ«£¬¸ù¾ÝÁ½ÖÖ̽ÕëÔÓ½»ÐźÅÇ¿Èõ£¬¿ÉÅж¨±»²âλµã»ùÒòÐÍ£¬Ê¡Ê±¡£¢Û̽ÕëÍË »ðζÈΪ58Ê¿2¡ãC£¬ÔÚ42¡ãCÔÓ½»¿É»ñµÃÂúÒâµÄÔÓ½»Ð§¹û£»¢ÜоƬ°üº¬¼ì²âϵͳºÍÖÊ¿ØÏµÍ³ Á½¸öÌåϵ£¬¿Éϵͳ¼ì²â2ÐÍÌÇÄò²¡Ïà¹Ø18¸öÒ׸лùÒòλµã£¬²¢ÓÐÖÊÁ¿¿ØÖÆ£»Î»µãº­¸ÇÁËÄ¿ ǰÒÑÈ·¶¨µÄÓë2ÐÍÌÇÄò²¡Ò׸лùÒòÃ÷È·Ïà¹ØµÄ»ùÒòλµã¡£Ïà¶ÔÓÚĿǰ³£ÓõÄSNaPshotºÍ Sequenom¼¼Êõ£¬¸ÃоƬ·½·¨²»ÐèÒªÌØÊâµÄ°º¹óÒÇÆ÷£¬ÊµÑéÊÒ³£¹æµÄÓ«¹âÏÔ΢¾µ¼´¿É½øÐмì²â¡£¸ÃоƬÊÊÓÃÓÚ´óÑù±¾µÍ³É±¾2ÐÍÌÇÄò²¡Ò׸лùÒò¹ØÁª·ÖÎö¡£


ͼ1Ϊ2ÐÍÌÇÄò²¡Ò׸лùÒò18¸öλµãÍ»±äλµã¼ì²â΢ÕóÁÐоƬµãÑù¾ØÕóͼ£¬Æä ÖС¤ÎªÑôÐÔ¶ÔÕÕ£»©–ΪÒõÐÔ¶ÔÕÕ(Ë«ÕôË®)£» ΪµãÑùÒº¶ÔÕÕ(µãÑùÈÜÒºMicro Spotting Solution Plus 2X£¬Telechem) £»¡òΪ·ÇÒ׸еÈλ»ùÒò¼ì²â̽Õ룻¦¨ÎªÒ׸еÈλ»ùÒò¼ì²â̽ Õ룻ͼ2ΪCy3±ê ¼Ç18¸öÍ»±äλµã¼ì²â΢ÕóÁв£Á§Ð¾Æ¬¼ì²â½á¹û£¬Í¬Ò»±ê±¾Æ½ÐÐ×öÁ½ ¾ØÕóÖØ¸´¶ÔÕÕ¡£Í¼3Ϊ΢ÕóÁÐоƬ¼ì²âµÄ18¸öÒ׸лùÒòλµã²âµÃ»ùÒòÐͲâÐòÑéÖ¤½á¹ûͼ¡£
¾ßÌåʵʩÀý·½Ê½ÒÔÏÂͨ¹ý¾ßÌåʵʩÀýÀ´½øÒ»²½ËµÃ÷±¾·¢Ã÷£¬µ«²»ÓÃÀ´ÏÞÖÆ±¾·¢Ã÷µÄ·¶Î§¡£ÈôÎ´ÌØ ±ðÖ¸Ã÷£¬ÊµÊ©ÀýÖÐËùÓõļ¼ÊõÊÖ¶ÎΪ±¾ÁìÓò¼¼ÊõÈËÔ±ËùÊìÖªµÄ³£¹æÊֶΡ£ÊµÊ©Àý1̽ÕëºÍÒýÎïÉè¼Æ±¾·¢Ã÷ͨ¹ý¶Ô2ÐÍÌÇÄò²¡Ò׸лùÒòλµãÍ»±ä½øÐÐɸѡ£¬Éè¼ÆÏà¹ØÌ½Õ룬¾­¹ý·´¸´ ÊÔÑéɸѡºÍÑéÖ¤£¬µÃµ½ÁËÒ»×éÔÓ½»ÌØÒìÐÔ¸ß׼ȷ¶ÈºÃµÄ̽Õ룬̽ÕëÐòÁÐÈç±í1Ëùʾ¡£±í1 18¸öλµãÒ°ÉúÐͺÍÍ»±äÐÍ̽ÕëÐòÁÐ
ȨÀûÒªÇó
Ò»ÖÖ¼ì²â2ÐÍÌÇÄò²¡18»ùÒòλµãÍ»±äµÄ»ùÒòоƬ£¬Æä°üÀ¨¹Ì¶¨ÔÚ¹ÌÏàÔØÌåÉϵÄÓÃÓÚ¼ì²â2ÐÍÌÇÄò²¡Ò׸лùÒòµÄÌØÒìÐԹѺËÜÕËá̽Õ룬ÆäºËÜÕËáÐòÁÐÈçSEQ ID No.1~36Ëùʾ¡£
2.¸ù¾ÝȨÀûÒªÇó1ËùÊöµÄ»ùÒòоƬ£¬ÆäÌØÕ÷ÔÚÓÚ£¬ËùÊö¹ÌÏàÔØÌåΪȩ»ù²£Æ¬¡£
3.¸ù¾ÝȨÀûÒªÇó2ËùÊöµÄ»ùÒòоƬ£¬ÆäÌØÕ÷ÔÚÓÚ£¬ËùÊö̽Õë5¡¯¶ËÓÐ15¸ö¶à¾ÛT£¬5¡¯¶Ë ¾­ÐÞÊΰ±»ù»ùÍźó¹Ì¶¨ÔÚÈ©»ù²£Æ¬ÉÏ¡£
4.¸ù¾ÝȨÀûÒªÇó1-3ËùÊö»ùÒòоƬ£¬ÆäÌØÕ÷ÔÚÓÚ£¬¸Ã»ùÒòоƬµãÕ󲼿ز£Á§Ð¾Æ¬Îª 117¸öÑùµã×é³ÉµÄ10ÐÐX 12ÁеľØÕ󣬰üÀ¨ÖÊ¿ØÏµÍ³ºÍ¼ì²âϵͳ£¬ÖÊ¿ØÏµÍ³Îª(1)оƬÑô ÐÔ¶ÔÕÕ£¬ÎªSEQ ID No.¹ã36̽ÕëµÄµÈÁ¿»ìºÏµÄÈÜÒº£¬×÷ΪÑôÐÔ¶ÔÕյ㣬Éè¼Æ²¼¿ØÓÚ×óϽǣ¬ ¹²3¸öÑôÐÔ¶ÔÕÕÑùµã£»(2)оƬƽÐжÔÕÕ£¬²ÉÓÃ25uMµÄ̽ÕëÈÜÒºµãÑù£¬Ã¿ÖÖ̽ÕëÉèÖÃÆ½ÐÐ µã3¸öµã£¬¼´Ã¿3¸öµã¼ì²âÒ»¸öµÈλ»ùÒòÐÍ£»×óÓÒ¹²6¸öµã£¬¹²Í¬¹¹³ÉÒ»¸ö»ùÒòλµã¼ì²âÇø£» (3)оƬÒõÐÔ¶ÔÕÕ£¬ÎªµãÑùÈÜÒºÒÔ¼°Ë«ÕôË®£¬¸÷Èý¸öµã£¬¹²6¸öÒõÐÔ¶ÔÕÕÑùµã£¬Î»ÓÚÓÒϽǡ£
5.ȨÀûÒªÇó¹ã4ÈÎÒ»ÏîËùÊö»ùÒòоƬµÄÖÆ±¸·½·¨£¬Æä°üÀ¨Èçϲ½ÖèºÏ³ÉSEQID No.¹ã36ËùʾµÄ̽Õ룬̽ÕëÔںϳÉʱ5¡¯¶Ë¶àºÏ³É15¸ö¶à¾ÛT£¬²¢¾­°±»ù»ùÍÅÐÞÊΣ¬½«ÐÞÊκó µÄ̽ÕëÓÃTE BufferÖÆ³É50uMµÄÈÜÒº£¬µãÑùǰ°´1 1±ÈÀýÓëµãÑùÈÜÒº»ìºÏ£¬ÖÕŨ¶ÈΪ25 mM £»½«²£Æ¬È©»ù»¯ÐÞÊΣ»½«ÖÕŨ¶ÈΪ25mMµÄ̽ÕëÈÜÒº°´µãÑù¾ØÕóÅÅÁÐÔÚ96¿×°å£»PBSÈÜÒº ÇåÏ´µãÑùÒǵãÑùÕ룬УÕý£¬°´Í¼1¾ØÕóµãÑù£»Ô¤µã20´Î£¬µã¼ä¼ä¾à200um£¬ÊÒÎÂË®ºÏ¹Ì¶¨24h¡£
6.¸ù¾ÝȨÀûÒªÇó5ËùÊöµÄ·½·¨£¬ÆäÌØÕ÷ÔÚÓÚ£¬Æä»¹°üÀ¨Ôڹ̶¨ºó°´ÏÂÊö²½Öè½øÐÐÏ´µÓ ÊÒÎÂÏÂ2XSSC-0. P/oSDSÏ´µÓÒºÖÐÉÏÏÂÌá·Å2-3´Î£¬1XSSC-0. 1% SDSÏ´µÓÒºÖÐÉÏÏÂÌá·Å 2min, 0. 2 X SSCÏ´µÓÒºÖÐÉÏÏÂÌá·Å2min£¬Ë«ÕôË®ÖгéÌá2_3´Î£¬ÀëÐÄ˦¸É¡£
7.º¬ÓÐȨÀûÒªÇó¹ã4ÈÎÒ»ÏîËùÊö»ùÒòоƬµÄÊÔ¼ÁºÐ¡£
8.¸ù¾ÝȨÀûÒªÇó7ËùÊöµÄÊÔ¼ÁºÐ£¬Æä»¹°üÀ¨ÓÃÓÚÀ©ÔöÒ׸лùÒòλµãËùÔÚÇøÓòµÄÒýÎ ÒýÎïÐòÁÐΪSEQ ID No. 37 72ËùʾµÄ¹ÑºËÜÕËᣬËùÀ©ÔöÇøÓòΪSEQ ID No. 73 90Ëùʾ¡£
9.¸ù¾ÝȨÀûÒªÇó7»ò8ËùÊöµÄÊÔ¼ÁºÐ£¬Æä°üÀ¨ÒÔÏÂÊÔ¼ÁÖеÄÒ»ÖÖ»ò¶àÖÖÔÓ½»Òº¡¢·â±Õ Òº¡¢PCR»º³åÒº¡¢dNTPs¡¢DNA¾ÛºÏøÒÔ¼°MgCl2¡£
È«ÎÄÕªÒª
±¾·¢Ã÷¹«¿ªÁËÒ»ÖÖ¼ì²â2ÐÍÌÇÄò²¡Ò׸лùÒò18¸öλµãÍ»±äµÄ»ùÒòоƬ¡£¸ÃоƬÒԹ̶¨ÔÚ¹ÌÏàÔØÌåÉϵÄSEQIDNo.1~36ËùʾµÄ̽Õë×÷Ϊ¼ì²âϵͳ£¬²¢½øÒ»²½°üÀ¨ÑôÐÔ¶ÔÕÕ¡¢ÒõÐÔ¶ÔÕÕºÍÆ½ÐжÔÕÕ×é³ÉÖÊ¿ØÏµÍ³°ü¡£±¾·¢Ã÷»¹Í¬¿ªÁ˸ûùÒòоƬ¼ì²âµÄÅäÌ×ÒýÎÕâЩÒýÎï¿ÉÔÚͬһÍË»ðζȽøÐÐPCR·´Ó¦£¬À©ÔöͬʱÍê³ÉCy3±ê¼Ç£¬¾­¹ý1´ÎÔÓ½»·´Ó¦£¬¼´¿É¼ì²â18¸ö»ùÒòλµã¡£¼ì²â½á¹û׼ȷ¡¢¿ìËÙ¡¢Ð§Âʸߣ¬Äܹ»ÏµÍ³µØÉ¸Ñ¡Ä¿Ç°¹úÄÚÍⱨµ¼µÄ2ÐÍÌÇÄò²¡Ò׸лùÒò18¸öλµãÍ»±ä£¬ÊÊÓÃÓÚ´óÑù±¾µÍ³É±¾2ÐÍÌÇÄò²¡Ò׸лùÒò¹ØÁª·ÖÎö¡£
Îĵµ±àºÅG01N21/64GK101956017SQ20101051827
¹«¿ªÈÕ2011Äê1ÔÂ26ÈÕ ÉêÇëÈÕÆÚ2010Äê10ÔÂ22ÈÕ ÓÅÏÈȨÈÕ2010Äê10ÔÂ22ÈÕ
·¢Ã÷Õß¶¡·å, ÁõËÉ÷, ÖÜÐÂ, Áº´¿×Ó, Íõ´º·¼, Ô¬æÂ, лìÍ, µË¹Ú»ª, Ö£è¯, Âíº£²¨ ÉêÇëÈË:¹ãÖÝÑôÆÕÒ½ÁƿƼ¼¹É·ÝÓÐÏÞ¹«Ë¾;Î人´óѧ

  • רÀûÃû³Æ£ºÒ»ÖÖÓÃÓÚ²úÆ·ÄÍˮѹ¼ì²âµÄ¼ìÑéÖξ߽ÓÍ·µÄÖÆ×÷·½·¨¼¼ÊõÁìÓò£º±¾ÊµÓÃÐÂÐÍÉæ¼°Ò»ÖÖÓÃÓÚ²úÆ·ÄÍˮѹ¼ì²âµÄ¼ìÑéÖξß¡£ ±³¾°¼¼Êõ£º²úÆ·ÄÍˮѹ¼ì²âʱµÄÃÜ·â¼¼Êõ£¬Ò»°ãʹÓÃÊг¡²É¹ºµÄÉúÁÏ´øÃÜ·âÂÝÎÆ£¬ÊÖ¹¤Å¡½ô ÂÝÎÆ¡£´Ë·½·¨´æÔÚÒÔÏÂȱµã1.¼ì²âǰ½«½ÓÍ·(
  • רÀûÃû³Æ£º£ºÊ±¼ä²âÁ¿µç·¡¢Ê±¼ä²âÁ¿·½·¨¡¢ÒÔ¼°Ê¹ÓÃÆäµÄʱ¼äÊý×Öת»»Æ÷ºÍ²âÊÔ×°ÖõÄÖÆ×÷·½·¨¼¼ÊõÁìÓò£º£º±¾·¢Ã÷Éæ¼°Ò»ÖÖʱ¼ä²âÁ¿¼¼Êõ¡£±³¾°¼¼Êõ£º£º¹«ÖªÓн«µÚ1ÐźÅ(ÒÔϳÆÎª¿ªÊ¼ÐźÅ)ºÍµÚ2ÐźÅ(Í£Ö¹ÐźÅ)µÄ¹ý¶É¶¨Ê±µÄʱ¼ä²îת»»ÎªÊý×ÖÖµµÄʱ¼äÊý×Öת»»
  • רÀûÃû³Æ£º¶àÆÕÀÕÐͳ¬ÉùÁ÷Á¿¼ÆµÄÖÆ×÷·½·¨¼¼ÊõÁìÓò£º±¾·¢Ã÷Éæ¼°Ò»ÖÖ¶àÆÕÀÕÐͳ¬ÉùÁ÷Á¿¼Æ£¬Ëüͨ¹ý²ÉÓó¬Éù²¨µÄ¶àÆÕÀÕÆ«ÒÆÓÃÀ´²âÁ¿Òª²âÁ¿µÄÁ÷ÌåµÄÁ÷¶¯ËÙÂÊ(a flow rate)£¬¸ü¾ßÌ嵨£¬±¾·¢Ã÷Éæ¼°Ò»ÖÖ¶àÆÕÀÕÐͳ¬ÉùÁ÷Á¿¼Æ£¬ËüÔÊÐí×Ô¶¯µØµ÷½ÚºÍÉ趨³¬Éù²¨
  • רÀûÃû³Æ£º»ð³µÂÖ¶ÔÂäÂÖÔÚÏß×Ô¶¯¼ì²âÉ豸µÄÖÆ×÷·½·¨¼¼ÊõÁìÓò£º±¾·¢Ã÷Éæ¼°Ò»Öֻ𳵳µÂÖÂÖ¶ÔÂäÂÖ×Ô¶¯¼ì²âÉ豸¡£±³¾°¼¼Êõ£º½üÄêÀ´Ëæ×Ż𳵵Ķà´ÎÌáËÙ£¬»ð³µÂÖ¶ÔµÄÄ¥Ëð¼Ó¾ç£¬Òò´Ë£¬¶¨ÆÚ¶ÔÂֶԵĸ÷¹Ø¼üÃæ³ß´ç¡¢ÐÎ×´Îó²îÒÔ¼°Î»Öþ«¶È½øÐо«ÃÜ×Ô¶¯¼ì²âÊÇÈ·±£³µÁ¾ÐÐÊ»
  • רÀûÃû³Æ£º»ùÓڰͿ˺ÀÉ­Ô­ÀíµÄÓ¦Á¦¼ì²â×°ÖõÄÖÆ×÷·½·¨¼¼ÊõÁìÓò£º±¾ÊµÓÃÐÂÐÍÉæ¼°Ò»ÖÖ»ùÓڰͿ˺ÀÉ­Ô­ÀíµÄÓ¦Á¦¼ì²â×°Öã¬ÊÊÓÃÓÚ¼ì²â¸Ö¹ìµÄÓ¦Á¦ºÍÔ¤²â¸Ö¹ìµÄÆ£ÀÍ״̬£¬±£Ö¤¸Ö¹ì¸ÉÏß°²È«Í¨ÐС£±³¾°¼¼Êõ£ºÌú´ÅÐÔ²ÄÁϾßÓÐÁ¼ºÃµÄµ¯ÐÔ¡¢ËÜÐÔ£¬²¢ÇÒ¾ßÓмáÓ²¡¢Ä͸¯¡¢ÊµÓÃ
  • רÀûÃû³Æ£ºÒ»ÖÖ±³×ê°å±³×êÉî¶È²âÊÔ×°ÖõÄÖÆ×÷·½·¨¼¼ÊõÁìÓò£º±¾ÊµÓÃÐÂÐÍÊôÓÚÓ¡ÖÆÏß·°å¼¼ÊõÁìÓò£¬Éæ¼°Ò»ÖÖ±³×ê°å±³×êÉî¶È²âÊÔ×°Öᣠ±³¾°¼¼Êõ£º×î½ü¼¸Ä꣬µç×ÓÐÐÒµÔÚ°ëµ¼Ìå¼¼ÊõºÍÉè¼Æ¼¼ÊõµÄ´ø¶¯Ï£¬´ó·ù¶È’ñÓÃHDI (¸ßÃÜ¶È »¥Á¬Ïß·)Éè¼Æ¼¼Êõ£¬×îΪÈËËù
ɽ¶«ÑÇÐÇÓÎÏ·¹ÙÍø»ú´²ÓÐÏÞ¹«Ë¾
È«¹ú·þÎñÈÈÏߣº13062023238
µç»°£º13062023238
µØÖ·£ºëøÖÝÊÐÁúȪ¹¤ÒµÔ°68ºÅ
¹Ø¼ü´Ê£ºÏ³´²£¬Êý¿ØÏ³´²£¬ÁúÃÅϳ´²
¹«Ë¾¶þάÂë
Copyright 2010-2024 °æÈ¨ËùÓÐ All rights reserved ³ICP±¸19044495ºÅ-12
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿